Hormone Resistant Prostate Cancer Terminated Phase 2 Trials for Saracatinib (DB11805)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01267266Saracatinib in Treating Patients With Prostate CancerTreatment